Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Sep;41(9):2035–2036. doi: 10.1128/aac.41.9.2035

Synergistic activities of clarithromycin and pyrazinamide against Mycobacterium tuberculosis in human macrophages.

N Mor 1, A Esfandiari 1
PMCID: PMC164062  PMID: 9303411

Abstract

The combination of clarithromycin and pyrazinamide was found to be synergistic against Mycobacterium tuberculosis in human macrophages. MICs were four- to eightfold lower for this combination than they were for either drug alone. Clarithromycin and rifampin, however, had only an additive effect.

Full Text

The Full Text of this article is available as a PDF (140.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bass J. B., Jr, Farer L. S., Hopewell P. C., O'Brien R., Jacobs R. F., Ruben F., Snider D. E., Jr, Thornton G. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention. Am J Respir Crit Care Med. 1994 May;149(5):1359–1374. doi: 10.1164/ajrccm.149.5.8173779. [DOI] [PubMed] [Google Scholar]
  2. Biehle J., Cavalieri S. J. In vitro susceptibility of Mycobacterium kansasii to clarithromycin. Antimicrob Agents Chemother. 1992 Sep;36(9):2039–2041. doi: 10.1128/aac.36.9.2039. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brown B. A., Wallace R. J., Jr, Onyi G. O., De Rosas V., Wallace R. J., 3rd Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. Antimicrob Agents Chemother. 1992 Jan;36(1):180–184. doi: 10.1128/aac.36.1.180. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cavalieri S. J., Biehle J. R., Sanders W. E., Jr Synergistic activities of clarithromycin and antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1995 Jul;39(7):1542–1545. doi: 10.1128/aac.39.7.1542. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Crowle A. J., Sbarbaro J. A., May M. H. Inhibition by pyrazinamide of tubercle bacilli within cultured human macrophages. Am Rev Respir Dis. 1986 Nov;134(5):1052–1055. doi: 10.1164/arrd.1986.134.5.1052. [DOI] [PubMed] [Google Scholar]
  6. Davidson P. T., Le H. Q. Drug treatment of tuberculosis--1992. Drugs. 1992 May;43(5):651–673. doi: 10.2165/00003495-199243050-00003. [DOI] [PubMed] [Google Scholar]
  7. Ferebee S. H. Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc. 1970;26:28–106. [PubMed] [Google Scholar]
  8. Fernandes P. B., Hardy D. J., McDaniel D., Hanson C. W., Swanson R. N. In vitro and in vivo activities of clarithromycin against Mycobacterium avium. Antimicrob Agents Chemother. 1989 Sep;33(9):1531–1534. doi: 10.1128/aac.33.9.1531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gorzynski E. A., Gutman S. I., Allen W. Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycin. Antimicrob Agents Chemother. 1989 Apr;33(4):591–592. doi: 10.1128/aac.33.4.591. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hardy D. J., Guay D. R., Jones R. N. Clarithromycin, a unique macrolide. A pharmacokinetic, microbiological, and clinical overview. Diagn Microbiol Infect Dis. 1992 Jan;15(1):39–53. doi: 10.1016/0732-8893(92)90055-x. [DOI] [PubMed] [Google Scholar]
  11. Ji B., Perani E. G., Grosset J. H. Effectiveness of clarithromycin and minocycline alone and in combination against experimental Mycobacterium leprae infection in mice. Antimicrob Agents Chemother. 1991 Mar;35(3):579–581. doi: 10.1128/aac.35.3.579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Konno K., Feldmann F. M., McDermott W. Pyrazinamide susceptibility and amidase activity of tubercle bacilli. Am Rev Respir Dis. 1967 Mar;95(3):461–469. doi: 10.1164/arrd.1967.95.3.461. [DOI] [PubMed] [Google Scholar]
  13. Salfinger M., Crowle A. J., Reller L. B. Pyrazinamide and pyrazinoic acid activity against tubercle bacilli in cultured human macrophages and in the BACTEC system. J Infect Dis. 1990 Jul;162(1):201–207. doi: 10.1093/infdis/162.1.201. [DOI] [PubMed] [Google Scholar]
  14. Sbarbaro J. A., Iseman M. D., Crowle A. J. Combined effect of pyrazinamide and ofloxacin within the human macrophage. Tuber Lung Dis. 1996 Dec;77(6):491–495. doi: 10.1016/s0962-8479(96)90045-3. [DOI] [PubMed] [Google Scholar]
  15. Sbarbaro J. A., Iseman M. D., Crowle A. J. The combined effect of rifampin and pyrazinamide within the human macrophage. Am Rev Respir Dis. 1992 Dec;146(6):1448–1451. doi: 10.1164/ajrccm/146.6.1448. [DOI] [PubMed] [Google Scholar]
  16. Truffot-Pernot C., Lounis N., Grosset J. H., Ji B. Clarithromycin is inactive against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1995 Dec;39(12):2827–2828. doi: 10.1128/aac.39.12.2827. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES